Intermolecular interactions and permeability of 5-fluorouracil cocrystals with a series of isomeric hydroxybenzoic acids: a combined theoretical and experimental study

5-Fluorouracil (5FU) is a BCS class III drug with good aqueous solubility and poor permeability, which severely limits its transdermal permeation through the stratum corneum. Herein, four cocrystals of 5FU with a series of isomeric hydroxybenzoic acids, including salicylic acid (2 : 1), 3-hydroxyben...

Full description

Saved in:
Bibliographic Details
Published inCrystEngComm Vol. 21; no. 34; pp. 595 - 515
Main Authors Dai, Xia-Lin, Voronin, Alexander P, Gao, Wei, Perlovich, German L, Lu, Tong-Bu, Chen, Jia-Mei
Format Journal Article
LanguageEnglish
Published Cambridge Royal Society of Chemistry 2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:5-Fluorouracil (5FU) is a BCS class III drug with good aqueous solubility and poor permeability, which severely limits its transdermal permeation through the stratum corneum. Herein, four cocrystals of 5FU with a series of isomeric hydroxybenzoic acids, including salicylic acid (2 : 1), 3-hydroxybenzoic acid (1 : 1) and 4-hydroxybenzoic acid (forms I and II, 1 : 1) were prepared and subjected to membrane permeation. They exhibited significantly improved membrane permeability due to the lipid solubility enhancement caused by cocrystallization. Solid-state DFT computations followed by Bader analysis based on single crystal structures were carried out to quantify the pattern of non-covalent interactions in the cocrystals. The lattice energy values were estimated as a sum of energies of non-covalent intermolecular interactions, which show a negative correlation with the lipid solubility of 1 : 1 cocrystals. This study has important implications for the use of the cocrystallization approach to improve the permeability of transdermal drugs. This work combined theoretical and experimental methods to explore intermolecular interactions and permeability of 5-fluorouracil cocrystals with isomeric hydroxybenzoic acids.
Bibliography:For ESI and crystallographic data in CIF or other electronic format see DOI
Electronic supplementary information (ESI) available: CCDC
10.1039/c9ce00661c
1885425
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:1466-8033
1466-8033
DOI:10.1039/c9ce00661c